Skip to content
fulcrum
Contact
filing to 30 June 2026

// payment practices, as filed · company 02487574

Bristol-Myers Squibb Pharmaceuticals Ltd: how it pays its suppliers, from its own filing

Bristol-Myers Squibb Pharmaceuticals Ltd reports paying its suppliers in an average of 50 days, with 21% of invoices paid later than the agreed terms, for the period 1 January 2026 to 30 June 2026. Across the 1,496 companies that report on construction contracts, the median is 31 days and 14% late. Every figure below is the company’s own, approved by a director and published on the government register; this page reproduces it and says what it means for a subcontractor.

50 days

Average days to pay

longer than 86% of the 1,496 filers; median 31 days

21%

Paid later than agreed

a higher share than 64% of filers; median 14%

36%

Paid within 30 days

37% took longer than 60 days

The terms it declares

Standard payment terms
0 to 90 days
Maximum contractual period
90 days
Paid in 31 to 60 days
27%
Paid after 60 days
37%
Not paid because of a dispute
84%
Filed on
17 August 2026

Their standard terms, in their words

The preferred BMS terms for 3rd party vendors are default to 90 days. Payment terms are outlined in contracts with suppliers. Where a contract is not negotiated, the payment terms will be clearly stated on the Purchase Orders (POs) sent to suppliers. Any changes to the payment terms would require a contract amendment. For Health Care Professionals the standard payment terms are immediate, therefore meeting these terms are difficult to achieve when we consider time to send the invoice, process, approve and release for payment, currently 73% of the above reported late payments are due to Imme…

Their explanation

NA

Every filing since Jun 2018

Bristol-Myers Squibb Pharmaceuticals Ltd has filed 15 times. The share paid late is down 1 points on the previous filing, and the average days to pay up 5 days. The first filing, for the period to 30 June 2018, reported 39 days and 40% late.

Bristol-Myers Squibb Pharmaceuticals Ltd: share of invoices paid late (bars) and average days to pay (line), every filing since H1 180%25%50%0d30d60dH1 18H2 18H1 19H2 19H1 20H2 20H1 21H2 21H1 22H2 22H1 23H2 23H1 25H2 25H1 26BARS: PAID LATER THAN AGREEDLINE: AVERAGE DAYS TO PAY
The last six filings by Bristol-Myers Squibb Pharmaceuticals Ltd
Period toDays to payPaid lateWithin 30 daysOver 60 days
30 June 20265021%36%37%
31 December 20254522%38%29%
30 June 20255022%35%31%
31 December 20234227%41%22%
30 June 20234227%41%21%
31 December 20224024%43%20%

Retention

This filing declares no retention clauses in its construction contracts. If your subcontract with Bristol-Myers Squibb Pharmaceuticals Ltd does hold retention, the contract governs; the retention piece explains how to get it released.

What this means if you are pricing work for them

The share paid later than agreed is the number to read first, because a short term makes an invoice late sooner and a long one hides lateness inside the term. Bristol-Myers Squibb Pharmaceuticals Ltd is above the median on that measure, so build the delay into your cash flow before you sign. The average days to pay sits over the median.

A worked example on a 30-day term: an invoice of £10,000.00 paid on this company’s average, 20 days after the final date, carries £64.38 of statutory interest at 11.75% plus the fixed sum, £164.38 in all, which the law lets you add without a clause. Run your own figures.

Against the official benchmark: the Department for Business and Trade’s statistics for 2025, published 14 July 2026, put large construction businesses at 33 days to pay with 14% of invoices late by number (13% by value), and all large businesses at 32 days and 15% late. Bristol-Myers Squibb Pharmaceuticals Ltd is slower than the sector figure. Its late share is above the sector figure.

What the register does not show: it is self-reported, large companies only, and the filing covers the whole company, not your contract. Read it alongside the notice rules that decide what you are actually owed, and keep your own dates.

Questions subcontractors ask about Bristol-Myers Squibb Pharmaceuticals Ltd

How long does Bristol-Myers Squibb Pharmaceuticals Ltd take to pay its suppliers?
Bristol-Myers Squibb Pharmaceuticals Ltd reported an average of 50 days to pay an invoice for 1 January 2026 to 30 June 2026, with 36% of invoices paid within 30 days and 37% taking longer than 60 days. The official 2025 figure for large construction businesses is 33 days.
Does Bristol-Myers Squibb Pharmaceuticals Ltd pay late?
By its own filing, 21% of Bristol-Myers Squibb Pharmaceuticals Ltd's invoices were paid later than the agreed terms, against 14% across large construction businesses in 2025 and a median of 14% among the 1,496 companies on this register that declare construction contracts. That is down 1 points on its previous filing (22% for the period to 31 December 2025).
Does Bristol-Myers Squibb Pharmaceuticals Ltd hold retention?
Bristol-Myers Squibb Pharmaceuticals Ltd declares no retention clauses in its construction contracts in this filing. Your subcontract governs; if it holds retention, the contract terms decide when it is released.
Can I charge Bristol-Myers Squibb Pharmaceuticals Ltd interest on a late invoice?
Yes, under the Late Payment of Commercial Debts (Interest) Act 1998, from the day after the final date for payment, at 8% over the Bank of England base rate plus a fixed sum per invoice, without any clause in the contract. The calculator works it out for your figures.

Source: the company’s own report on the government’s payment practices service, report 116492, made under the Reporting on Payment Practices and Performance Regulations 2017 and reproduced under the Open Government Licence v3.0. Register copy taken 2 October 2026; comparisons are against the latest filing of each of the 1,496 companies declaring construction contracts. Figures are as filed, not judged. Not legal advice.